Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What Trade-Offs Do Consumers And Physicians Make In Choosing Rx Drug Treatments?

Executive Summary

US FDA study is to examine the relative importance of product information, such as efficacy, risk and patient preference claims, in the treatment preferences of consumers and physicians.

You may also be interested in...

Do Patients Understand The Term ‘Median’ In Advertising? US FDA Aims To Find Out

In first Rx advertising research project of 2023, FDA will survey consumers on how they interpret quantitative claims in DTC ads. Lilly questions design of another study examining relative importance of product information, citing FDA comments at tanezumab advisory committee.

Pitching Drugs To Physicians: Disclosing Limitations Of Clinical Data May Be Beneficial

US FDA study finds that sales aids for oncology drugs that disclose a study’s data limitations and clinical uncertainty can lead to more appropriate assessments of the data by physicians but does not affect their overall perceptions of a drug’s benefits.

Rx Drug Promotion: Inclusion Of Extensive Risk Info In Twitter, Google Ads Has Potential Drawback

US FDA study of character-space-limited prescription drug communications finds consumers may be less likely to click on a link for more risk information if the promo already has substantial details.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts